Literature DB >> 6416162

In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

M H Cynamon, G S Palmer.   

Abstract

The comparative in vitro activity of amoxicillin alone and in combination with clavulanic acid against 15 isolates of Mycobacterium tuberculosis was evaluated by broth dilution susceptibility testing. Amoxicillin inhibited 4 of 15 isolates at 8 micrograms/ml or less but was not bactericidal against any of the isolates at that concentration. Amoxicillin in combination with clavulanic acid was bactericidal for 14 of 15 isolates tested at an amoxicillin concentration of 4 micrograms/ml or less and a clavulanic acid concentration of 2 micrograms/ml or less.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6416162      PMCID： PMC185338          DOI： 10.1128/AAC.24.3.429

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  beta-Lactamase activity in slow-growing nonpigmented mycobacteria and their sensitivity to certain beta-lactam antibiotics.

Authors:  J E Kasik; M Monick; B Schwarz
Journal:  Tubercle       Date:  1980-12

2.  In vitro susceptibility of Mycobacterium fortuitum to N-formimidoyl thienamycin and several cephamycins.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191
  2 in total
  39 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

2.  Reconsidering some approved antimicrobial agents for tuberculosis.

Authors:  Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 3.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

4.  In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.

Authors:  M Casal; F Rodriguez; M Benavente; M Luna
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

Review 5.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

6.  Oldie but goodie: Repurposing penicillin for tuberculosis.

Authors:  Amanda B Keener
Journal:  Nat Med       Date:  2014-09       Impact factor: 53.440

7.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

8.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors:  Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

10.  Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  C Segura; M Salvadó; I Collado; J Chaves; A Coira
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.